Case 1 – Maintenance treatment with trabectedin in advanced soft tissue sarcomas: when should we consider progression?

 

Authors

  • Diego Soto de Prado y Otero Oncology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Jesús Angel Palencia Ercilla Traumatology and Ortophedics Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
  • Alejandro León Andrino Traumatology and Ortophedics Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
  • Mercedes Alonso Rodríguez Nuclear Medicine Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Gerardo Martínez García Pathological Anatomy Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Laura Casadiego Matarranz Radiology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Silvia Hernansanz de la Calle Oncology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Bruno Vincenzi Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy

DOI:

https://doi.org/10.19156/cbn.2016.0017

Keywords:

maintenance treatment, RECIST criteria, response evaluation, soft tissue sarcoma, trabectedin

Abstract

We present the case of a patient with a locally advanced synovial sarcoma treated with neoadjuvant chemotherapy and subsequent surgery who presented an early metastatic relapse, wherein a rapid and significant response was achieved with trabectedin, and in whom maintenance of the drug until clinical progression of the disease allowed 27 cycles of treatment to be administered despite the patient presenting radiological progression according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria 15 cycles earlier.

Downloads

Published

2016-07-15

How to Cite

1.
de Prado y Otero DS, Ercilla JAP, Andrino AL, Rodríguez MA, García GM, Matarranz LC, de la Calle SH, Vincenzi B. Case 1 – Maintenance treatment with trabectedin in advanced soft tissue sarcomas: when should we consider progression?  . CBN [Internet]. 2016 Jul. 15 [cited 2024 Nov. 24];4(2):42-7. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/213

Issue

Vol. 4 No. 2 (2016): July 2016

Section

Meet the expert

License

Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.